Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03214172

Enrollment

1000

Registered

2017-07-11

Start date

2017-07-15

Completion date

2017-09-15

Last updated

2018-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous Thromboembolism

Brief summary

To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with rivaroxaban

Interventions

DRUGRivaroxaban (Xarelto, BAY59-7939)

15/20 mg

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients (≥18 years-of-age) with active cancer * Patient with at least one index venous thromboembolism (VTE ) * ≥6-months of continuous eligibility prior to the index VTE event (baseline period). * Newly initiated on rivaroxaban

Exclusion criteria

* Patients with any medical claim for Deep vein thrombosis (DVT) or Pulmonary embolism (PE) during the 6 months pre-index date * Patients with prescription claim for anticoagulation therapy during the 6-month pre-index VTE period

Design outcomes

Primary

Measure	Time frame	Description
Recurrent Venous thromboembolism	Retrospective analysis from November 2012 through September 2015	Derived using inpatient and outpatient medical claims
Bleeding (based on the Cunningham algorithm)	Retrospective analysis from November 2012 through September 2015	Derived using inpatient and outpatient medical claims
Mortality (In-hospital mortality or need for hospice care without subsequent healthcare claims)	Retrospective analysis from November 2012 through September 2015	Derived using inpatient and outpatient medical claims

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026